Japan completes trio of major filings for Anoro Ellipta
This article was originally published in Scrip
Executive Summary
The Japanese approval filing for GlaxoSmithKline and partner Theravance's bronchodilator Anoro Ellipta marks the completion of submissions in the world's three largest pharma markets for the chronic obstructive pulmonary disease (COPD) therapy.